Stock markets have largely two types of investors. One type who spend time in the market and another who time the market. Picking High growth stocks at the most opportune time. Seldom there is an occasion when interests of both the types are in unison. Here are two such ASX 200 stocks
ANZ Group Holdings Limited (ASX: ANZ)
In 2024, ANZ Group Holdings Limited (ASX: ANZ) marked a pivotal year with significant strategic moves, including the completion of its purchase of Suncorp Bank and the sale of its AmBank shares. The bank is among the best growth stocks to buy now having achieved a record result from its Institutional division and gained momentum with its digital banking platform, ANZ Plus. This platform aims to enhance customers' financial wellbeing, with features such as My Accounts, which allows customers to import data from other Australian banks using Open Banking. ANZ also introduced ANZ Transactive Global, a secure, configurable platform that supports businesses with a wide range of banking services, including cash management, trade finance, and data insights. With a resilient, low-cost, and agile business model, ANZ is positioning itself for a dual-platform future that balances traditional banking with modern digital solutions.
ANZ is among the best dividend growth stocks. Its overall structure is divided into three key segments: Banking, Markets, and Group Centre. The Banking division, which contributes around 90% of Group revenue, focuses on lending, trade, deposits, and payments services. It has successfully optimized net interest margin (NIM) and return on equity (ROE). The Markets division, contributing about 10% of Group revenue, acts as an intermediary for risk management solutions and complements the Banking business. The Group Centre is focused on cost efficiency and capital optimization, providing operational support and treasury functions. This diverse structure has enabled ANZ to maintain solid performance despite challenging economic conditions, such as inflation and high interest rates.
ANZ's New Zealand operations reported a modest increase in profit for FY24, with a 1% rise in cash net profit after tax (NPAT) to $2,286 million, despite facing tough market conditions. The bank reduced its credit impairment provision, reflecting lower expected loan defaults. In terms of performance, ANZ NZ saw steady growth in home lending, while its business lending portfolio contracted slightly due to external factors. For FY25, ANZ NZ is focused on maintaining a strong financial position and preparing for an economic recovery, while continuing to balance growth with margin optimization.
Fisher & Paykel Healthcare Corporation Limited (ASX: FPH)
Fisher & Paykel Healthcare Corporation Limited, is one of the potential growth companies having reported a strong financial performance for the 2024 fiscal year, marking a return to growth after several years of fluctuating demand. Operating revenue rose 10% from the comparable period last year-or 8% in constant currency-for $1.74 billion. The firm reported net profit after tax for the quarter to be $132.6 million, which was mainly affected by three abnormal items of land valuation adjustments, changes in tax deductions for building depreciation, and a voluntary product recall. Excluding these factors, the underlying net profit was $264.4 million, reflecting a 6% increase over the prior year.
In terms of product performance, the Hospital product group saw revenue of $1.1 billion, growing by 6%, with consumable sales returning to pre-COVID patterns. The Homecare product group, driven by strong demand for respiratory products like the Evora Full mask, reached a record revenue of $652.3 million, an 18% increase from the previous year. The company also highlighted progress in R&D, with new product launches such as the Airvo 3 and 950 systems in the Hospital segment, and new masks like F&P Solo and F&P Nova Micro in Homecare.
Fisher & Paykel is among the growing companies to invest in as it is also making significant strides in improving its margins, with an underlying gross margin of 61.1%, up from 59.8% in the previous year. This was driven by lower freight costs and improved manufacturing efficiencies. The company declared a dividend of 23.5 cents per share for the second half of the year, making a total dividend of 41.5 cents per share for the year, thus reflecting an increase of 2% compared with last year 2023.
The company expects continued growth in 2025. Its operating revenue for the first half of the financial year will range from $940 million to $950 million, while net profit after tax in the range of $150 million to $160 million. Full year revenue guidance is expected within the range of $1.9 billion to $2.0 billion, and net profit guidance has been increased now into the range of $320 million to $370 million. The company anticipates strong contributions from both its Hospital and Homecare product groups, driven by new product introductions and positive market trends, positioning them well to meet their long-term growth targets.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.